320 related articles for article (PubMed ID: 36831539)
1. Hyponatremia and Cancer: From Bedside to Benchside.
Fibbi B; Marroncini G; Naldi L; Anceschi C; Errico A; Norello D; Peri A
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831539
[TBL] [Abstract][Full Text] [Related]
2. Clinical review: the use of vaptans in clinical endocrinology.
Peri A
J Clin Endocrinol Metab; 2013 Apr; 98(4):1321-32. PubMed ID: 23401044
[TBL] [Abstract][Full Text] [Related]
3. [Vasopressin antagonists in treatment of hyponatremia].
Olszewski W; Głuszek J
Pol Arch Med Wewn; 2007 Aug; 117(8):356-62. PubMed ID: 18018383
[TBL] [Abstract][Full Text] [Related]
4. Vasopressin dysregulation and hyponatremia in hospitalized patients.
Multz AS
J Intensive Care Med; 2007; 22(4):216-23. PubMed ID: 17712057
[TBL] [Abstract][Full Text] [Related]
5. V2 receptor antagonist; tolvaptan.
Yi JH; Shin HJ; Kim HJ
Electrolyte Blood Press; 2011 Dec; 9(2):50-4. PubMed ID: 22438856
[TBL] [Abstract][Full Text] [Related]
6. Vaptans for the treatment of hyponatremia.
Robertson GL
Nat Rev Endocrinol; 2011 Mar; 7(3):151-61. PubMed ID: 21283124
[TBL] [Abstract][Full Text] [Related]
7. Vasopressin receptor antagonists and their role in clinical medicine.
Narayen G; Mandal SN
Indian J Endocrinol Metab; 2012 Mar; 16(2):183-91. PubMed ID: 22470853
[TBL] [Abstract][Full Text] [Related]
8. Vaptans: A new option in the management of hyponatremia.
Aditya S; Rattan A
Int J Appl Basic Med Res; 2012 Jul; 2(2):77-83. PubMed ID: 23776817
[TBL] [Abstract][Full Text] [Related]
9. Tolvaptan Treatment in Children with Chronic Hyponatremia due to Inappropriate Antidiuretic Hormone Secretion: A Report of Three Cases.
Tuli G; Tessaris D; Einaudi S; De Sanctis L; Matarazzo P
J Clin Res Pediatr Endocrinol; 2017 Sep; 9(3):288-292. PubMed ID: 28515029
[TBL] [Abstract][Full Text] [Related]
10. The V
Marroncini G; Anceschi C; Naldi L; Fibbi B; Baldanzi F; Maggi M; Peri A
J Endocrinol Invest; 2022 Sep; 45(9):1693-1708. PubMed ID: 35604542
[TBL] [Abstract][Full Text] [Related]
11. Tolvaptan in the treatment of acute hyponatremia associated with acute kidney injury.
Gopinath S; Janga KC; Greenberg S; Sharma SK
Case Rep Nephrol; 2013; 2013():801575. PubMed ID: 24558627
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
Nemerovski C; Hutchinson DJ
Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
[TBL] [Abstract][Full Text] [Related]
13. Unpredictable nature of tolvaptan in treatment of hypervolemic hyponatremia: case review on role of vaptans.
Malhotra I; Gopinath S; Janga KC; Greenberg S; Sharma SK; Tarkovsky R
Case Rep Endocrinol; 2014; 2014():807054. PubMed ID: 24511399
[TBL] [Abstract][Full Text] [Related]
14. Hyponatremia, fluid-electrolyte disorders, and the syndrome of inappropriate antidiuretic hormone secretion: diagnosis and treatment options.
Siragy HM
Endocr Pract; 2006; 12(4):446-57. PubMed ID: 16901803
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients.
Nodari S; Jao GT; Chiong JR
Int J Nephrol Renovasc Dis; 2010; 3():51-60. PubMed ID: 21694929
[TBL] [Abstract][Full Text] [Related]
16. Role of vaptans in the management of hyponatremia.
Lehrich RW; Ortiz-Melo DI; Patel MB; Greenberg A
Am J Kidney Dis; 2013 Aug; 62(2):364-76. PubMed ID: 23725974
[TBL] [Abstract][Full Text] [Related]
17. [Vasopressin receptor antagonists: the vaptans].
Villabona C
Endocrinol Nutr; 2010 May; 57 Suppl 2():41-52. PubMed ID: 21130961
[TBL] [Abstract][Full Text] [Related]
18. The use of vasopressin receptor antagonists in hyponatremia.
Khanna A; Menon MC
Curr Opin Investig Drugs; 2010 Sep; 11(9):1007-14. PubMed ID: 20730695
[TBL] [Abstract][Full Text] [Related]
19. Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet.
Gross PA; Wagner A; Decaux G
Kidney Int; 2011 Sep; 80(6):594-600. PubMed ID: 21451459
[TBL] [Abstract][Full Text] [Related]
20. Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V₂-receptor antagonist tolvaptan.
Gaglio P; Marfo K; Chiodo J
Dig Dis Sci; 2012 Nov; 57(11):2774-85. PubMed ID: 22732834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
